Related Experiment Video
Updated: Jun 11, 2025
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated encephalitis induced by Mycoplasma pneumoniae
Yan-Ru Liu1, Xiang-Dong Zeng2, Ying Xiong3
1Department of Pediatric Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Background:
This study aims to report the phenomenon of Myelin oligodendrocyte glycoprotein antibody-associated encephalitis induced by Mycoplasma pneumoniae infections and promote the potential benefits of combining early immunotherapy and anti-M-pneumoniae therapy for these patients.
Methods:
Three children with MOG-IgG-associated encephalitis due to M. pneumoniae infections who were treated at our hospital from September to November 2023 were included in the study. We investigated and analyzed the background and clinical features of these patients.
Results:
Three patients developed headaches, seizures, and/or other neurological manifestations, elevated mononuclear cells in cerebrospinal fluid, intracranial lesions on cranial magnetic resonance imaging (MRI), and positive MOG-IgG in serum, within 10-14 days. They were diagnosed with MOG-IgG-associated encephalitis due to M. pneumoniae infections, the treatment consisted of intravenous immunoglobulin, glucocorticoid, and erythromycin, then they were completely recovered.
Conclusion:
Mycoplasma pneumoniae (M. pneumoniae) infections can cause oligodendrocyte glycoprotein (MOG) antibody-associated encephalitis. The recognition of this condition will promote the potential benefits of combining early immunotherapy and anti-M. pneumoniae therapy for patients with MOG-IgG-associated encephalitis.
Insights
Mycoplasma pneumoniae infections can trigger Myelin oligodendrocyte glycoprotein antibody-associated encephalitis in children. Early immunotherapy combined with antibiotics offers a promising treatment approach for this condition.
Area of Science:
- Neurology
- Infectious Diseases
- Immunology
Background:
- Mycoplasma pneumoniae infections are common, but their association with neurological disorders is increasingly recognized.
- Myelin oligodendrocyte glycoprotein antibody-associated encephalitis (MOG-IgG-AE) is an inflammatory demyelinating disease of the central nervous system.
- The link between M. pneumoniae and MOG-IgG-AE requires further investigation to understand the underlying mechanisms.
Purpose of the Study:
- To report a series of pediatric cases of MOG-IgG-AE triggered by M. pneumoniae infection.
- To highlight the clinical features and diagnostic challenges of this specific encephalitis.
- To emphasize the potential therapeutic benefits of combined early immunotherapy and anti-M. pneumoniae treatment.
Main Methods:
- Retrospective analysis of three pediatric patients diagnosed with MOG-IgG-AE and M. pneumoniae infection between September and November 2023.
- Detailed investigation of patient demographics, clinical presentations, cerebrospinal fluid analysis, and neuroimaging findings (MRI).
- Evaluation of treatment protocols, including immunotherapy and antimicrobial therapy, and patient outcomes.
Main Results:
- Three children presented with neurological symptoms including headaches and seizures, accompanied by elevated cerebrospinal fluid mononuclear cells and intracranial lesions on MRI.
- All patients tested positive for MOG-IgG in serum and were diagnosed with M. pneumoniae-associated MOG-IgG-AE within 10-14 days of infection onset.
- Treatment with intravenous immunoglobulin, glucocorticoids, and erythromycin resulted in complete recovery for all three patients.
Conclusions:
- M. pneumoniae infection can serve as a trigger for MOG-IgG-AE in pediatric patients.
- Prompt diagnosis and combined treatment of early immunotherapy and anti-M. pneumoniae therapy are crucial for favorable outcomes.
- This study underscores the importance of considering M. pneumoniae as a potential causative agent in MOG-IgG-AE and advocates for integrated therapeutic strategies.
More Related Videos
08:03Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
10:47Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
Published on: October 27, 2016
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...